ReachMD

Be part of the knowledge.™

Surgery

52

LikeLikedUnlike

Episodes 1-15 of 16

Closing the Gap to Care: Assessing CAD and Improving Patient Outcomes with Revascularization
CME/CE
Closing the Gap to Care: Assessing CAD and Improving Patient Outcomes with Revascularization
- Adam DeVore, MD
  Peer
- Lauren Barron, MD
  Peer
- Navin Kapur, MD
  Peer
0.50 credits
Talking Rare: Epidemiology and Pathogenesis of APOL1-Mediated Kidney Disease
CME/CE
Talking Rare: Epidemiology and Pathogenesis of APOL1-Mediated Kidney Disease
- Martin Pollak, MD
  Peer
- Susanne Nicholas, MD, MPH, PhD
  Peer
0.25 credits
Optimizing Bone Health in Postmenopausal Post-Fracture Patients
CME/CE
Optimizing Bone Health in Postmenopausal Post-Fracture Patients
- Andrea Singer, MD, FACP, CCD
  Peer
- Susan V. Bukata, MD, FAOA, FAAOS
  Peer
0.25 credits
Preoperative Concerns Regarding Neoadjuvant Therapy and Delays in Surgery
Minute CME/CE™
Preoperative Concerns Regarding Neoadjuvant Therapy and Delays in Surgery
- Brian Gastman, MD
  Peer
2.25 program credits
Who Is Eligible for Neoadjuvant or Adjuvant Immunotherapy?
Minute CME/CE™
Who Is Eligible for Neoadjuvant or Adjuvant Immunotherapy?
- Brian Gastman, MD
  Peer
2.25 program credits
Lack of Concordance Between Radiologic and Pathologic Responses in Neoadjuvant ICI Treatment of Melanoma: How Do I Assess Radiologic Progression?
Minute CME/CE™
Lack of Concordance Between Radiologic and Pathologic Responses in Neoadjuvant ICI Treatment of Melanoma: How Do I Assess Radiologic Progression?
- Brian Gastman, MD
  Peer
2.25 program credits
What Are the Data Supporting Neoadjuvant Therapy in Melanoma?
Minute CME/CE™
What Are the Data Supporting Neoadjuvant Therapy in Melanoma?
- Jeffrey S. Weber, MD, PhD
  Peer
2.25 program credits
Minute CME/CE™
Integrating Immune Checkpoint Therapy Into the Management of Resectable Melanoma
- Jeffrey S. Weber, MD, PhD
  Peer
- Brian Gastman, MD
  Peer
- Michael T. Tetzlaff, MD, PhD
  Peer
2.25 credits 12 episodes
Panel: Preserving Operability: How To Manage irAEs in the Perioperative Setting During Neoadjuvant Treatment of Melanoma?
Minute CME/CE™
Panel: Preserving Operability: How To Manage irAEs in the Perioperative Setting During Neoadjuvant Treatment of Melanoma?
- Jeffrey S. Weber, MD, PhD
  Peer
- Brian Gastman, MD
  Peer
2.25 program credits
Panel: Discussing Neoadjuvant/Adjuvant ICI-Based Therapy With Patients and Caregivers
Minute CME/CE™
Panel: Discussing Neoadjuvant/Adjuvant ICI-Based Therapy With Patients and Caregivers
- Jeffrey S. Weber, MD, PhD
  Peer
- Brian Gastman, MD
  Peer
- Michael T. Tetzlaff, MD, PhD
  Peer
2.25 program credits
Panel: Critical Considerations in the Use of ICIs in High-Risk Resectable Melanomas
Minute CME/CE™
Panel: Critical Considerations in the Use of ICIs in High-Risk Resectable Melanomas
- Jeffrey S. Weber, MD, PhD
  Peer
- Brian Gastman, MD
  Peer
- Michael T. Tetzlaff, MD, PhD
  Peer
2.25 program credits
Should a Patient With a BRAF-Mutated Tumor Receive Targeted vs ICI Neoadjuvant Therapy?
Minute CME/CE™
Should a Patient With a BRAF-Mutated Tumor Receive Targeted vs ICI Neoadjuvant Therapy?
- Jeffrey S. Weber, MD, PhD
  Peer
2.25 program credits
Panel: How and When Should I Assess Response to Neoadjuvant and Adjuvant ICI Therapy?
Minute CME/CE™
Panel: How and When Should I Assess Response to Neoadjuvant and Adjuvant ICI Therapy?
- Brian Gastman, MD
  Peer
- Michael T. Tetzlaff, MD, PhD
  Peer
2.25 program credits
What Are the Data Supporting Adjuvant Therapy in Melanoma?
Minute CME/CE™
What Are the Data Supporting Adjuvant Therapy in Melanoma?
- Jeffrey S. Weber, MD, PhD
  Peer
2.25 program credits
What Is the Rationale for Neoadjuvant and Adjuvant Therapy in Melanoma?
Minute CME/CE™
What Is the Rationale for Neoadjuvant and Adjuvant Therapy in Melanoma?
- Jeffrey S. Weber, MD, PhD
  Peer
2.25 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended